Machina Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Machina Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22	Closed	-$882	–	475
2023 Q1	$882	Buy	+22	New	+$944	﹤0.01%	475

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Machina Capital's RARE Position: Q2 2023 in Review

Machina Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2023, closing a stake of 22 shares — an estimated $882 sold.

Machina Capital first reported a position in RARE in Q1 2023 and held it in 1 quarter. The position peaked at $882 in Q1 2023. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2023.

Machina Capital reported no remaining Ultragenyx Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Machina Capital sold 22 Ultragenyx Pharmaceutical shares in Q2 2023, an estimated $882.
Machina Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2023 and held it in 1 quarter.
Machina Capital's Ultragenyx Pharmaceutical position peaked at $882 in Q1 2023.
242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2023.

Based on Machina Capital's 13F filing for Q2 2023, filed 8 Aug 2023.